Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3500 | STP + COVID-19 Convalescent Plasma (CP) Wiki | 1.00 |
| drug3501 | STP + Standard Plasma (SP) Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
To date no specific treatment has been proven to be effective for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) infection. It is possible that convalescent plasma that contains antibodies to SARS-Cov-2 might be effective against the progression of infection. Promising results have been shown by preliminary data from China cases. The investigators planned to compare effectiveness of adding COVID-19 convalescent plasma to standard therapy protocol (STP) versus adding plasma donated in pre-COVID era versus STP alone in patient with COVID-19 within 5 days from the onset of respiratory distress. STP at enrolment is the best evidence based therapy approved for treatment of COVID patients by regional Health system emergency committee.
Description: Proportion of patients alive 30 days after randomization
Measure: 30-days survival Time: 30 days after randomizationDescription: Cumulative incidence of mechanical ventilation or death
Measure: Ventilator free survival Time: 30 days after randomizationDescription: Probability of being alive at 6 months after randomization
Measure: 6-months survival Time: 6 months after randomizationDescription: Proportion of patients developing any serious medical or procedure related complications
Measure: Incidence of complications Time: Within 12 monthsDescription: Proportion of days spent in ICU on the total length of hospital stay
Measure: Days in intensive care units (ICU) Time: From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Proportion of patients showing seroconversion to Immunoglobulin G (IgG) anti-SARS-Cov-2
Measure: Positivity for Immunoglobulin G to SARS-Cov-2 Time: On day 0, 2, 4, 6,10,14, 21, 28 after randomization and at date of discharge or death from any cause, whichever came first, assessed up to 12 monthsDescription: Proportion of patients showing viral clearance by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) on plasma and respiratory tract samples
Measure: Clearance of viral load Time: On day 0, 2, 4, 6,10,14, 21, 28 after randomization and at date of discharge or death from any cause, whichever came first, assessed up to 12 monthsDescription: Variations in SOFA Score (range 0-24; higher score mean a worse outcome)
Measure: Sequential Organ Failure Assessment (SOFA) score Time: On day 0, 2, 4, 6, 10, 14, 28 after randomization and at date of discharge or death from any cause, whichever came first, assessed up to 12 monthsDescription: Proportion of patients needing introduction of new drug or discontinuation of drug from standard therapy protocol
Measure: Any variation from Standard Therapy Protocol Time: From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed daily up to 2 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports